

One Embarcadero Center
Suite 2700
San Francisco, CA 94111-3776
PHONE (415) 591-5400
FAX (415) 591-5401
E-MAIL burrill@b-c.com
WEB www.burrillandco.com

G. STEVEN BURRILL
CHIEF EXECUTIVE OFFICER

G. Steven Burrill is Chief Executive Officer of Burrill & Company, a San Francisco based life sciences firm focused exclusively on companies involved in biotechnology, pharmaceuticals, diagnostics, devices, human healthcare and related medical technologies, nutraceuticals and wellness, agricultural biotechnology, and industrial biotechnology (biomaterials/bioprocesses). Burrill & Company's business revolves around three core activities: Venture Capital, Merchant Banking and The Burrill Life Sciences Media Group (a joint venture with Nielsen Media). In these activities, Burrill & Company seeks to create value through developing significant equity stakes in its portfolio companies which benefit from Burrill & Company's unparalleled network in the life science community. In addition to the company's staff of over 50, Burrill & Company calls upon the members of its advisory boards for counsel. These boards are composed of former chief executives of major pharmaceutical, and biotech companies; industry luminaries; world-renowned scientists; and Nobel Laureates.

The Burrill family of venture capital funds, with over \$900 million under management, includes the Burrill Life Sciences Capital Fund II and Burrill Life Sciences Capital Fund I (comprised of the Burrill Biotechnology Fund, the Burrill Agbio Capital Fund and its successor—the Burrill Agbio Capital Fund II, the Burrill Ag Annex and the Burrill Nutraceuticals Capital Fund). Burrill & Company recently completed raising its Burrill Life Sciences Capital Fund III, a \$273 million fund, which closed in 2006. Additionally, Burrill & Company recently commenced raising a new fund, The Burrill Global Select Healthcare Fund, a €500 million publicly listed fund investing in public life science companies.

Mr. Burrill has devoted his career to helping life science companies launch their operations and sustain their growth in the face of a constant and rapidly changing environment. In 2002, he was recognized as the biotech investment visionary by the prestigious *Scientific American* magazine (The Scientific American 50). He currently serves as Chairman of the Board of Pharmasset (NASDAQ: VRUS) and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed (NASDAQ: DEPO), Intranasal, Phytomedics, Proteogenix, Proventys, Targacept (NASDAQ: TRGT) and XDx.

Mr. Burrill is a founder of The Biotech Meeting at Laguna Niguel (now in its 20th year); The China/India Life Sciences Partnering Meetings; The Japan Biotech Meeting, The Stem Cell Summit, The Personalized Medicine Meeting, and The Health and Wellness Meeting. These annual events enable Burrill & Company to remain on the

cutting edge of the industry to maintain strong ties with the leading companies, CEOs, and the most promising technologies—making Burrill & Company the “best networked” company in the industry.

Prior to founding Burrill & Company in 1994, Mr. Burrill spent 28 years with Ernst & Young (through 1993) directing and coordinating the firm’s services to clients in the biotechnology/life sciences and high technology/manufacturing industries worldwide. He was the International Chairman of the Life Sciences/Biotechnology and Manufacturing/High Technology practices (responsible for approximately one-third of the firm’s then \$6.5 billion business). His E&Y experience included working with ALZA, Amgen, Calgene, Chiron (Cetus), Collagen, Corixa (Anergen), Genentech, Gilead Sciences, InSite Vision, SciClone, Sequus (now part of ALZA), and Terrapin from their inception.

As an internationally recognized spokesman for the life sciences and high technology industries, Mr. Burrill has authored a variety of articles and books about the business, management and financial concerns of life science, high tech and high growth companies. In addition, Mr. Burrill has authored annual reports on the US and European biotechnology industry for the last 21 years. *Biotech 2007— A Global Transformation* is Mr. Burrill’s newest edition.

In addition to his work with leading life science companies, Mr. Burrill also chaired the National Research Council study on linkages in biotechnology between Japan and the United States. He was also involved with the US-Japan Science and Technology Agreement Study of Technology Transfer Mechanisms between the US and Japan. Mr. Burrill is a founder and currently serves as the Chairman of the Board of the Foundation for the National Medals of Science and Technology. Additionally, he serves as Chairman of the Board on Campaign for Medical Research as well as Chairman of the San Francisco Mayor’s Biotech Advisory Committee (MAYBAC). Other not-for-profit activities include serving on the Boards of Directors for the Bay Area Science Infrastructure Consortium, BayBio, California Healthcare Institute, The Exploratorium, Genetics Policy Institute, The Kellogg Center for Biotechnology, Kramden Institute, The National Health Museum, and Research!America. He also serves as an advisor on the MIT Center for Biomedical Innovation, Purdue Discovery Park External Advisory Committee as well as the editorial board of the Journal of Commercial Biotechnology.

Mr. Burrill earned his BBA in accounting and finance from the University of Wisconsin in Madison. He has four grown sons and nine grandchildren. He and his wife, Kelli, make their home in San Francisco.